To represent the sex of angels : trans/poetics : an exegesis presented in partial fulfilment of the requirements for the degree of Master of Fine Arts at Massey University, Wellington, New Zealand

Content removed due to copyright restrictions: Figure 4: Tsang, W., 2014, The Shape of a Right Statement, Installation view, NOGUERAS BLANCHARD, Mardrid. Retrieved from: http://moussemagazine.it/axolotlism-nogueras-blanchard/ ; Figure 7: Photographer unknown, 1914-1917, Dr von Dannevill October 1914 - June 1917, NZ Archives. Retrieved from: http://www.pridenz.com/image/000004.html?ref=1100 ; Figure 8: Weems, C., 2006, from the series Roaming, Photograph. Retreived from: http://carriemaeweems.net/galleries/roaming.html ; Figure 10: Mesiti, A., 2014, In the Ear of a Tyrant, Installation view,19th Biennale of Sydney, Art Gallery of NSW. Photograph: Sebastian Kriete. Retrieved from: http://www.angelicamesiti.com/selectedworks/#/in-the-ear-of-the-tyrant/This exegesis utilises writer Rebekah Edwards’ definition of ‘trans-poetics’ as a methodology for the creation of performative and moving image artworks. The linguistic categories within transpoetics are transcribed through a creative practice, valuing language for its multiplicity, ambiguity and limitations. The projects outlined in this exegesis focus on queer and trans histories lifted from archival documentation. Trans-poetics are employed to circumvent and rearticulate the problematic legacy of queer and trans representation. The aim of this research is to utilise and push beyond the established oeuvre of queer autoethnographic work. To take the waters (2017) and Hardening (2017) are two moving image works formed in response to the life and events surrounding the internment of Hjelmar Von Danneville on Matiu Somes Island in 1917. As works of significance, they are clear distillations of modes and methods of transpoetics used in response to narratives within historical material

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme

EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

EBVDNA and DLBC

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are 6450 years of age and compared this patient group to patients who are >50 years. In patients who are 6450 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG 652). Comparing EBV+ DLBCL patients in 6450 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme